Study objectives~To identify the incidence of upper respiratory tract symptoms: fever, cough and breathing difficulties, other symptoms suggestive of COVID-19 infection, respiratory tract infections suggestive of COVID-19, and COVID-19 confirmed by laboratory testing among the UK MS population~To establish if some DMDs increase the risk of COVID-19 infection~To determine the incidence and effectiveness of self-isolation in the MS population. To examine the impact self-isolation has on mood, fatigue, and other routinely collected patient reported outcome measures from the MS Register.~To determine the clinical outcome of respiratory tract infections, including confirmed and suspected cases of COVID-19, in terms of symptoms, time to recovery, hospital admission, requirement for ventilation, and death.~To determine the longer-term impact of COVID-19 on MS, using routinely collected MS outcomes in the MS register, including impact on disability, relapses and changes in DMDs as assessed at 3 monthly intervals.~To determine where people are obtaining their health information during the COVID-19 outbreak.~To establish changes in DMDs prior to and as a result of symptoms related and unrelated to COVID-19
The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.